Squarex Announces Positive Results from Completed Phase 2 Study of SQX770 in the Prevention of Recurrent Herpes Labialis |
| August 05, 2019 | August 2019 Bond Updates |
|
ST. PAUL, Minn., Aug. 5, 2019 /PRNewswire/ -- Squarex, a clinical-stage pharmaceutical company developing a topical immunomodulator for the long-term prevention of recurrent cold sores and other infections caused by herpes simplex viruses, today announced positive results from a Phase 2... |
| View more at: https://www.prnewswire.com:443/news-releases/squarex-announces-positive-results-from-completed-phase-2-study-of-sqx770-in-the-prevention-of-recurrent-herpes-labialis-300896065.html |
| Related News |
|